Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: SkylineDx, TTC Oncology, LianBio

NEW YORK –  SkylineDx said this week that it has received a capital investment of undisclosed amount from US-based investment and advisory firm Novalis LifeSciences and from Netherlands-based Van Herk Investments. SkylineDx noted it is at a "critical growth stage," with its first products introduced in the US. Its dermatology program is focused on prognostic and predictive biomarker development covering melanoma and squamous cell carcinoma. With the new funding, SkylineDx aims to accelerate clinical adoption of its Merlin Test for melanoma.


TTC Oncology this week launched its equity crowdfunding campaign. The firm said it has received an initial investment of $100,000 from William Beck, a professor of pharmacology and molecular genetics at the University of Illinois, Chicago. The Edina, Minnesota-based biotech will use the investment as bridge financing for a planned Phase II trial to assess the activity of its breast cancer drug TTC-352 against physicians' choice of therapy and validate a predictive biomarker. The firm is developing TTC-352 as a treatment for estrogen receptor-positive metastatic breast cancer after failure of hormonal treatment. TTC Oncology previously raised $6 million to support a Phase I trial, which showed the drug had promising activity and was well tolerated.


LianBio said this week that the Health Commission and Medical Products Administration of Hainan Province in China has approved its drug infigratinib under the Named Patient Program (NPP) as a treatment for previously treated, advanced, unresectable cholangiocarcinoma characterized by FGFR2 fusions or rearrangements. The NPP is a pilot program in the Bo'ao Lecheng International Medical Tourism Pilot Zone, which aims to accelerate access to medicines that address an unmet need but aren't yet approved in mainland China. LianBio, based in Shanghai and Princeton, New Jersey, in-licensed rights to develop and commercialize infigratinib in mainland China, Hong Kong, and Macau from BridgeBio Pharma in 2020. Earlier this year, the US Food and Drug Administration approved the same advanced, FGFR2-rearranged cholangiocarcinoma indication for infigratinib (called Truseltiq in the US), where it is being codeveloped and co-commercialized by BridgeBio and Helsinn Group.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.